Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients
Maryam B. Lustberg(Yale Cancer Center), Jeffrey J. Chalmers(The Ohio State University), Clayton Deighan(The Ohio State University), Robert Wesolowski(The Ohio State University Wexner Medical Center), Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Alejandra Garcia-Villa(The Ohio State University), Erin Macrae(McGill University), Charles L. Shapiro(Tisch Hospital), Priya Balasubramanian(Arc of the United States), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Bhuvaneswari Ramaswamy(The Ohio State University), Sarah Carothers(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Michael Berger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Yongqi Wu(The Ohio State University), Brandon Miller(The Ohio State University), Thomas A. Summers(Walter Reed National Military Medical Center), Xueliang Pan(The Ohio State University)
Cited by 124
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
|JAMA|2017|357
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
|Nature Reviews Clinical Oncology|2023|296
Triple-negative breast cancer: promising prognostic biomarkers currently in development
|Expert Review of Anticancer Therapy|2020|236